newsfilter
← Latest News
PR Newswire·

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...